Intimation for update in U.S. FDA inspection of wholly owned subsidiary.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Limited informed BSE that its wholly owned subsidiary Medgel Private Limited underwent a US FDA inspection at its Pithampur, Madhya Pradesh manufacturing facility from 17th to 21st February 2025. The US FDA has classified the inspection as 'Voluntary Action Indicated' (VAI), which is a favourable outcome. The inspection has been formally 'closed' under 21 CFR 20.64(d)(3), with no further compliance action required. This is an update to a previous intimation dated 24th February 2025.
This is a positive regulatory development for shareholders, as the VAI classification means Medgel's facility meets acceptable standards with no mandatory corrective action. It removes regulatory uncertainty and supports the subsidiary's ability to continue supplying the US market, which should be viewed as a modest positive for the stock.